Regulatory FDA approves MSD’s Keytruda combinations for MIBC Pharmaceutical TechnologyThe FDA has approved two of MSD's anti-PD-1 therapies, Keytruda and Keytruda Qlex, along with Padcev, for adults with MIBC.OncologyRead full story pharminent July 13, 2026 (Last updated: July 13, 2026) Pharmaceutical Technology The FDA has approved two of MSD’s anti-PD-1 therapies, Keytruda and Keytruda Qlex, along with Padcev, for adults with MIBC. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Roche Scraps Two Ionis-Partnered Huntington’s Studies After Tominersen FailureNext: FDA Posts 14 New Rejection Letters Just Days After Confirming a Pause Related Stories Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026 Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd pharminent July 9, 2026 Regulatory EC approves AbbVie’s Tepkinly combination for follicular lymphoma pharminent July 7, 2026
